295 related articles for article (PubMed ID: 31127190)
21. Interference with the androgen receptor protein stability in therapy-resistant prostate cancer.
Lakshmana G; Baniahmad A
Int J Cancer; 2019 Apr; 144(8):1775-1779. PubMed ID: 30125354
[TBL] [Abstract][Full Text] [Related]
22. Targeting the PI3K/AKT Pathway Overcomes Enzalutamide Resistance by Inhibiting Induction of the Glucocorticoid Receptor.
Adelaiye-Ogala R; Gryder BE; Nguyen YTM; Alilin AN; Grayson AR; Bajwa W; Jansson KH; Beshiri ML; Agarwal S; Rodriguez-Nieves JA; Capaldo B; Kelly K; VanderWeele DJ
Mol Cancer Ther; 2020 Jul; 19(7):1436-1447. PubMed ID: 32371590
[TBL] [Abstract][Full Text] [Related]
23. Calcium/calmodulin-dependent kinase II plays an important role in prostate cancer cell survival.
Rokhlin OW; Taghiyev AF; Bayer KU; Bumcrot D; Koteliansk VE; Glover RA; Cohen MB
Cancer Biol Ther; 2007 May; 6(5):732-42. PubMed ID: 17387273
[TBL] [Abstract][Full Text] [Related]
24. KN-93 inhibits androgen receptor activity and induces cell death irrespective of p53 and Akt status in prostate cancer.
Rokhlin OW; Guseva NV; Taghiyev AF; Glover RA; Cohen MB
Cancer Biol Ther; 2010 Feb; 9(3):224-35. PubMed ID: 20023417
[TBL] [Abstract][Full Text] [Related]
25. Isosilybin B causes androgen receptor degradation in human prostate carcinoma cells via PI3K-Akt-Mdm2-mediated pathway.
Deep G; Oberlies NH; Kroll DJ; Agarwal R
Oncogene; 2008 Jun; 27(28):3986-98. PubMed ID: 18332867
[TBL] [Abstract][Full Text] [Related]
26. The PI3K/Akt inhibitor LY294002 reverses BCRP-mediated drug resistance without affecting BCRP translocation.
Imai Y; Yoshimori M; Fukuda K; Yamagishi H; Ueda Y
Oncol Rep; 2012 Jun; 27(6):1703-9. PubMed ID: 22426819
[TBL] [Abstract][Full Text] [Related]
27. Clusterin enhances AKT2-mediated motility of normal and cancer prostate cells through a PTEN and PHLPP1 circuit.
Bertacchini J; Mediani L; Beretti F; Guida M; Ghalali A; Brugnoli F; Bertagnolo V; Petricoin E; Poti F; Arioli J; Anselmi L; Bari A; McCubrey J; Martelli AM; Cocco L; Capitani S; Marmiroli S
J Cell Physiol; 2019 Jul; 234(7):11188-11199. PubMed ID: 30565691
[TBL] [Abstract][Full Text] [Related]
28. Targeting the PI3K/AKT pathway for the treatment of prostate cancer.
Sarker D; Reid AH; Yap TA; de Bono JS
Clin Cancer Res; 2009 Aug; 15(15):4799-805. PubMed ID: 19638457
[TBL] [Abstract][Full Text] [Related]
29. Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor.
Lin HK; Yeh S; Kang HY; Chang C
Proc Natl Acad Sci U S A; 2001 Jun; 98(13):7200-5. PubMed ID: 11404460
[TBL] [Abstract][Full Text] [Related]
30. The Ways of Actin: Why Tunneling Nanotubes Are Unique Cell Protrusions.
Ljubojevic N; Henderson JM; Zurzolo C
Trends Cell Biol; 2021 Feb; 31(2):130-142. PubMed ID: 33309107
[TBL] [Abstract][Full Text] [Related]
31. Interaction between docetaxel resistance and castration resistance in prostate cancer: implications of Twist1, YB-1, and androgen receptor.
Shiota M; Kashiwagi E; Yokomizo A; Takeuchi A; Dejima T; Song Y; Tatsugami K; Inokuchi J; Uchiumi T; Naito S
Prostate; 2013 Sep; 73(12):1336-44. PubMed ID: 23775496
[TBL] [Abstract][Full Text] [Related]
32. Non-genomic action of resveratrol on androgen and oestrogen receptors in prostate cancer: modulation of the phosphoinositide 3-kinase pathway.
Benitez DA; Pozo-Guisado E; Clementi M; Castellón E; Fernandez-Salguero PM
Br J Cancer; 2007 May; 96(10):1595-604. PubMed ID: 17486135
[TBL] [Abstract][Full Text] [Related]
33. Insulin-like growth factor-I promotes migration in human androgen-independent prostate cancer cells via the alphavbeta3 integrin and PI3-K/Akt signaling.
Montagnani Marelli M; Moretti RM; Procacci P; Motta M; Limonta P
Int J Oncol; 2006 Mar; 28(3):723-30. PubMed ID: 16465378
[TBL] [Abstract][Full Text] [Related]
34. Reciprocal positive regulation between Cx26 and PI3K/Akt pathway confers acquired gefitinib resistance in NSCLC cells via GJIC-independent induction of EMT.
Yang J; Qin G; Luo M; Chen J; Zhang Q; Li L; Pan L; Qin S
Cell Death Dis; 2015 Jul; 6(7):e1829. PubMed ID: 26203858
[TBL] [Abstract][Full Text] [Related]
35. Cell-specific regulation of androgen receptor phosphorylation in vivo.
Taneja SS; Ha S; Swenson NK; Huang HY; Lee P; Melamed J; Shapiro E; Garabedian MJ; Logan SK
J Biol Chem; 2005 Dec; 280(49):40916-24. PubMed ID: 16210317
[TBL] [Abstract][Full Text] [Related]
36. Nongenomic androgen activation of phosphatidylinositol 3-kinase/Akt signaling pathway in MC3T3-E1 osteoblasts.
Kang HY; Cho CL; Huang KL; Wang JC; Hu YC; Lin HK; Chang C; Huang KE
J Bone Miner Res; 2004 Jul; 19(7):1181-90. PubMed ID: 15177002
[TBL] [Abstract][Full Text] [Related]
37. Y-box binding protein-1 promotes castration-resistant prostate cancer growth via androgen receptor expression.
Shiota M; Takeuchi A; Song Y; Yokomizo A; Kashiwagi E; Uchiumi T; Kuroiwa K; Tatsugami K; Fujimoto N; Oda Y; Naito S
Endocr Relat Cancer; 2011 Aug; 18(4):505-17. PubMed ID: 21652770
[TBL] [Abstract][Full Text] [Related]
38. GCP-mediated growth inhibition and apoptosis of prostate cancer cells via androgen receptor-dependent and -independent mechanisms.
Tepper CG; Vinall RL; Wee CB; Xue L; Shi XB; Burich R; Mack PC; de Vere White RW
Prostate; 2007 Apr; 67(5):521-35. PubMed ID: 17252539
[TBL] [Abstract][Full Text] [Related]
39. Phosphoinositide 3-kinase-independent non-genomic signals transit from the androgen receptor to Akt1 in membrane raft microdomains.
Cinar B; Mukhopadhyay NK; Meng G; Freeman MR
J Biol Chem; 2007 Oct; 282(40):29584-93. PubMed ID: 17635910
[TBL] [Abstract][Full Text] [Related]
40. Iminoenamine based novel androgen receptor antagonist exhibited anti-prostate cancer activity in androgen independent prostate cancer cells through inhibition of AKT pathway.
Divakar S; Saravanan K; Karthikeyan P; Elancheran R; Kabilan S; Balasubramanian KK; Devi R; Kotoky J; Ramanathan M
Chem Biol Interact; 2017 Sep; 275():22-34. PubMed ID: 28757136
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
